Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating Tumor DNA in Neurofibromatosis Type 1: Translating Molecular Discovery into Clinical Surveillance.

Diagnostics (Basel, Switzerland)·2026
Same author

Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy.

Molecular diagnosis & therapy·2026
Same author

Dissecting the prognostic role of metabolic markers in lung neuroendocrine Tumors: The MONET study.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

ACY-1215 and bortezomib cooperatively disrupt NOTCH3 signaling and induce anti-tumor effects in T-ALL models.

Biomarker research·2026
Same author

PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: A multicentric real-world study.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Overcoming radioresistance in prostate cancer by targeting DNA damage repair.

Cancer letters·2025

Related Experiment Video

Updated: Jun 16, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Interferon-alpha as angiogenesis inhibitor: learning from tumor models.

Stefano Indraccolo1

  • 1Istituto Oncologico Veneto, IRCCS, Padova, Italy. stefano.indraccolo@unipd.it

Autoimmunity
|February 20, 2010
PubMed
Summary

Interferon-alpha (IFN-alpha) inhibits tumor angiogenesis by affecting endothelial cells and growth factor production. This cytokine shows therapeutic potential, but its impact on tumor invasion and metastasis requires further study.

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Related Experiment Videos

Last Updated: Jun 16, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Area of Science:

  • Oncology
  • Immunology
  • Vascular Biology

Background:

  • Interferon-alpha (IFN-alpha) is a cytokine with demonstrated therapeutic effects in tumor models.
  • IFN-alpha is recognized as a potent inhibitor of angiogenesis, the formation of new blood vessels.
  • Its anti-angiogenic mechanisms involve influencing tumor cell growth factor production and directly impacting endothelial cells.

Purpose of the Study:

  • To elucidate the multifaceted anti-angiogenic effects of IFN-alpha.
  • To explore the direct impact of IFN-alpha on endothelial cell (EC) function and gene expression.
  • To discuss strategies for targeted delivery of IFN-alpha for enhanced therapeutic outcomes.

Main Methods:

  • Analysis of IFN-alpha's effects on basic fibroblast growth factor, IL-8, and vascular endothelial growth factor expression in tumor cells.
  • Investigation of IFN-alpha's direct effects on EC proliferation and migration.
  • Examination of IFN-alpha-induced gene expression profiles in ECs.
  • Assessment of IFN-alpha's impact on tumor growth, hypoxia, and necrosis in xenograft and transgenic mouse models.

Main Results:

  • IFN-alpha inhibits tumor angiogenesis through multiple pathways, including reduced growth factor production and direct EC impairment.
  • IFN-alpha upregulates genes encoding negative regulators of angiogenesis in ECs, amplifying its anti-angiogenic activity.
  • In vivo studies show IFN-alpha induces hypoxia and necrosis in xenografts, while in transgenic models, it inhibits both vasculature and tumor cell proliferation, leading to necrosis-free regression.

Conclusions:

  • IFN-alpha possesses significant anti-angiogenic properties with therapeutic implications for cancer treatment.
  • The precise effects of IFN-alpha on tumor cell invasion and metastasis remain to be determined.
  • Targeted gene delivery strategies are being explored to ensure sustained, localized IFN-alpha production for effective anti-angiogenic therapy.